**Application of Spironolactone in Female Pattern Hair Loss**
Female pattern hair loss (FPHL), also known as androgenetic alopecia (AGA), is one of the most common types of hair loss in women.
Its typical manifestation is gradual thinning of hair on the crown, widening of the part line, while the frontal hairline is usually preserved.
Androgens play a key role in the pathogenesis: dihydrotestosterone (DHT) shortens the anagen phase of the hair follicle, converting terminal hairs into fine vellus hairs.
Spironolactone is a classic diuretic that also possesses antiandrogenic effects.
It directly blocks the effects of androgens on hair follicles by competitively binding to androgen receptors;
it also inhibits the activity of 5α-reductase, reducing the conversion of testosterone into the more potent DHT.
Therefore, spironolactone is used to counteract androgen-driven hair loss.
In clinical practice, spironolactone is primarily indicated for female patients with FPHL in the following situations:
(1) Accompanied by clinical manifestations of hyperandrogenism, such as acne, hirsutism, and menstrual irregularities;
(2) Inadequate response to topical minoxidil treatment;
(3) Desire for systemic treatment with oral medication and absence of contraindications.
The use of spironolactone for hair loss constitutes “off-label use.”
It is not currently FDA-approved for female pattern hair loss, but multiple clinical studies and guidelines support its efficacy.
A 2020 systematic review showed that spironolactone significantly improves hair density and diameter in women with hair loss,
especially in moderate to severe cases, and long-term use (at least 6–12 months) yields more stable results.
The usual starting dose is 25–50 mg per day, taken orally in 1–2 divided doses, gradually increased based on tolerance to 100–200 mg/day.
The target therapeutic dose is typically 100–150 mg/day, with divided dosing to reduce gastrointestinal irritation.
Efficacy generally begins to appear after 6 months of treatment, reaching a stable state after 12 months.
Side effects of spironolactone require strict attention.
The most common are menstrual disturbances (e.g., irregular periods, amenorrhea) and breast tenderness, related to its antiandrogenic effects.
Hyperkalemia is a dangerous but relatively rare side effect, more likely to occur in patients with renal insufficiency or those taking other potassium-sparing medications concurrently.
Some patients may experience dizziness, hypotension, drowsiness, and gastrointestinal discomfort.
Before treatment, the patient’s age, reproductive plans, and health status must be assessed.
Spironolactone can cause feminization of the male fetus; therefore, it is contraindicated in women who are planning pregnancy, pregnant, or breastfeeding.
All patients should have serum electrolytes and renal function tested before use, rechecked 1–2 months after starting, and then monitored every 3–6 months thereafter.
For patients with polycystic ovary syndrome (PCOS) or hyperandrogenism, the advantages of spironolactone are more pronounced.
It can also be combined with oral contraceptives (especially those containing antiandrogenic progestins like Diane-35)
to enhance the antiandrogenic effect and reduce side effects such as menstrual irregularities.
However, combination therapy requires the physician to weigh the risks on an individual basis.
It is worth noting that spironolactone is not suitable for all patients with female pattern hair loss.
If hair loss is primarily related to low estrogen states (e.g., postmenopause), thyroid dysfunction, iron deficiency anemia, or other non-androgenic factors,
spironolactone may have limited efficacy, and the underlying cause should be addressed first.
Current evidence-based medical evidence indicates that spironolactone is an effective and relatively safe second-line treatment option for female pattern hair loss.
Although its efficacy is not as extensively validated as that of minoxidil, multiple high-quality observational studies and small randomized controlled trials support its value.
A 2021 expert consensus published in the *Journal of the American Academy of Dermatology* listed it as one of the recommended treatments for female pattern hair loss.
Using spironolactone requires patience.
Hair loss treatment is slow to take effect; treatment must be continued for at least 6 months to judge efficacy.
If no improvement is seen after 12 months, discontinuation or a switch to another regimen may be considered.
Abrupt discontinuation will not cause rebound hair loss, but the underlying hair loss process will continue.
In summary, spironolactone improves female pattern hair loss through antiandrogenic mechanisms, with a moderate level of evidence.
The target population is clearly defined, but monitoring of electrolytes, renal function, and hormone levels under a physician’s guidance is necessary.
It is an important option in the hair loss treatment toolbox, but not suitable for everyone.
For reference only, not medical advice.